Prospective economic evaluation accompanying a trial of GM-CSF/IL-3 in patients undergoing autologous bone marrow transplantation for Hodgkin's and non-Hodgkin's lymphoma

Bone Marrow Transplantation

Volumn 21, Issue 6, 1998, Pages 607-614

  Schulman, K A ^a   Dorsainvil, D ^a   Yabroff, K R ^a   DiCesare, J ^b   Felser, J ^b   Eisenberg, J M ^a   Glick, H A ^c  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b Sandoz Pharma Ltd   (Switzerland)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Bone marrow transplantation; Clinical trials; Cost effectiveness analysis; Economic evaluation; Lymphoma; Quality adjusted survival; Utility

Indexed keywords

CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 3;

ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DOUBLE BLIND PROCEDURE; DRUG COST; ECONOMIC EVALUATION; FEMALE; HODGKIN DISEASE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NONHODGKIN LYMPHOMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL;

EID: 0031909587     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701142     Document Type: Article

References (28)

1. Brandt SJ, Peters WP, Atwater SK et al. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone-marrow transplantation. New Engl J Med 1988; 318: 869-876.
2. Lopez AF, Dyson PG, To LB et al. Recombinant human interleukin-3 stimulation of hematopoiesis in humans: loss of responsiveness with differentiation in the neutrophilic myeloid series. Blood 1988; 72: 1797-1804.
3. Ihle JN. Biomedical and biological properties of interleukin-3: a lymphokine mediating the differentiation of a lineage of cells which includes prothymocytes and mast-like cells. J Immunol 1983; 131: 282-287.
4. Goodman JW, Hall EA, Miller KL et al. Interleukin-3 promotes erythroid burst formation in serum free cultures without detectable erythropoietin. Proc Natl Acad Sci USA 1989; 128: 501-509.
5. Schulman KA, Glick HA, Yabroff KR, Eisenberg JM. Introduction to clinical economics: assessment of cancer therapies. J Natl Cancer Inst Monogr 1995; 19: 1-9.
6. Schulman KA, Yabroff KR. Measuring the cost-effectiveness of cancer care. Oncology 1995; 9: 523-537.
7. Welch GH, Larson EB. Cost effectiveness of bone marrow transplantation in acute nonlymphocytic leukemia. New Engl J Med 1989; 321: 807-812.
8. Uyl-de Groot CA, Hagenbeek A, Verdonck LF et al. Cost-effectiveness of ABMT in comparison with CHOP chemotherapy in patients with intermediate- and high-grade malignant non-Hodgkin's lymphoma (NHL). Bone Marrow Transplant 1995; 16: 463-470.
9. Smith TJ, Dosch CE, Hillner BE. Analysis of economic issues. In: Armitage JO; Antman KH (eds). High-Dose Cancer Therapy: Pharmacology Hemopoichins and Skin Cells. Williams & Wilkins: Baltimore, 1992, pp 127-139.
10. Smith TJ, Hillner BE, Schmitz N et al. Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous hone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma. J Clin Oncol 1997; 15: 1-10.
11. Fay JW, Felser JM, Abboud C et al. Sequential administration of recombinant human interleukin-3 (IL-3) and granulocyte-macrophage colony-stimulating factor (GM-CSF) after autologous bone marrow transplantation (ABMT) therapy for lymphoma: results of a phase III multi-center study. Blood 1995; 86: 222a.
12. Health Care Financial Administration. Revisions to payment policies and adjustments to the relative value units under the physician fee schedule for calendar year 1995; Final rule, Federal Register, December 2, 1995.
13. American Medical Association. Physicians' Current Procedural Terminology, CPT-4 '94. American Medical Association: Chicago, 1993.
14. Hsiao WC, Braun P, Dunn D, Becker ER. Resource-based relative values: an overview. J Am Med Assoc 1988; 260: 2347-2353.
15. Schulman KA, Willke R, Burke J, Glick HA. Multinational resource cost estimation methods. Presented at the Annual Meeting of the International Society of Technology Assessment in Health Care, 1997.
16. The International Classification of Diseases, 9th Revision, Clinical Modification. Commission on Professional and Hospital Activities: Ann Arbor, 1986.
17. Health Care Financing Administration. Hospital Cost Report Data: Minimum Data Set; 1993.
18. Medical Economics Company. The Red Book. Medical Economics Data: Montvale, 1995.
19. American Nurses Association: 1994 Average Salaries. Hospital and Health Care Report. Wyatt Data Services: Rochelle Park, April 1994.
20. National Association for Home Care. Basic Statistics About Home Care. 1995.
21. EuroQol Group: EuroQol: a new facility for the measurement of health-related quality of life. Health Policy 1990, pp 199-208.
22. Huber PJ. Robust estimation of a location parameter. Ann Math Stat 1964; 35: 73-101.
23. Schulman KA, Buxton M, Glick HA et al. Results of the economic evaluation of the FIRST study: a multinational prospective economic evaluation, Int J Technol Assess Health Care 1996; 12: 698-713.
24. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. John Wiley: New York, 1980.
25. Donham CS, Sensenig AL, Heffler SK. Health care indicators. Health Care Financing Rev 1995; 16: 243-272.
26. Bennett CL, Armitage JL, Armitage G et al. Costs of care and outcomes for high-dose therapy and autologous transplantation for lymphoid malignancies: results from the University of Nebraska 1987 through 1991. J Clin Oncol 1995; 13: 969-973.
27. Blumberg N, Heal JM, Kirkley SA et al. Leukodepleted-ABO-identical blood components in the treatment of hematologic malignancies: a cost analysis. Am J Hematol 1995; 48: 108-115.
28. Dickersin K. How important is publication bias? A synthesis of available data. AIDS Educ Prev 1907; (Suppl. A): 15-21.